1.98
-1.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pentixapharm Holding
Its shares trade on XETRA under the ticker PTP.DE. It has been listed since 3 October 2024. In the fiscal year to 31 December 2025, it reported revenue of €93,000 and a net loss of €16.5m. At that date it held total assets of €41.9m and shareholders' equity of €35.1m.
Pentixapharm Holding AG is a DE-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Berlin, Berlin. The company went IPO on 2024-10-03. Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The firm focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. The company is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 3 Oct 2024
- Website
- pentixapharm.com ↗
Leadership
Pay as last reported
- Dr. Andreas EckertChairman of the Supervisory Board, since 2024
- Dr. Hakim BouterfaChief Executive Officer, Member of the Management Board
- Dr. Harald HasselmannDeputy Chairman of the Supervisory Board, since 2024
- Mr. Jens GiltschMember of the Supervisory Board
- Prof. Dr. Ken HerrmannMember of the Supervisory Board
- Mr. Phillip EckertInvestor Relations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Germany-based clinical-stage radiopharmaceutical development company with focus on theranostics for blood cancer.
- Berlin headquarters provides access to a strong healthcare research ecosystem in Germany.
- Pentixapharm Holding AG's IPO on 3 October 2024 demonstrates market confidence in its development pipeline.
Weaknesses
- Pentixapharm Holding AG is a clinical-stage company with no commercial products yet.
- The company's focus on radiopharmaceuticals for blood cancer may limit market reach.
- Theranostics development requires significant R&D investment without guaranteed returns.
Opportunities
- Growing demand for theranostics in blood cancer treatment across Europe.
- Expansion into cardiovascular and endocrine disease markets with existing R&D capabilities.
- Collaboration opportunities with German healthcare institutions for clinical trials.
Threats
- Regulatory hurdles in radiopharmaceutical development across European markets.
- Competition from established pharmaceutical companies in the radiopharmaceutical sector.
- Economic downturns affecting healthcare R&D funding in Germany.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.